胶质母细胞瘤细胞治疗抵抗与转录组谱数据的整合分析识别联合放化疗的增敏脆弱点
该研究对一组人胶质母细胞瘤细胞系进行整合分析,用qRT-PCR检测38个DNA损伤应答调节因子的mRNA表达,用克隆形成存活实验评估对放疗(单次和分次模式)和/或替莫唑胺的固有抵抗,通过降维提取抵抗评分并与mRNA表达做相关分析。结果显示单次和分次放疗抵抗与PARP1、NBN、BLM、ATR和LIG4的mRNA表达强正相关,AZD-6738抑制ATR可稳健且剂量依赖地增敏,L189抑制LIG4无明显影响;替莫唑胺抵抗与MGMT及ATM表达强正相关,ATM抑制在MGMT低表达细胞中对替莫唑胺有轻微增敏。
要点
- 单次和分次放疗抵抗均与PARP1、NBN、BLM、ATR和LIG4的mRNA表达强正相关。
- AZD-6738抑制ATR可稳健且剂量依赖地增敏胶质母细胞瘤细胞,L189抑制LIG4无明显影响。
- 替莫唑胺抵抗与MGMT及ATM的mRNA表达强正相关,ATM抑制在MGMT低表达细胞中仅见轻微增敏。
核心结论
- 该研究描述了一种整合克隆形成存活数据与DNA损伤应答调节因子mRNA表达数据的系统方法,用于识别人胶质母细胞瘤细胞系固有治疗抵抗的标志物和靶向增敏的潜在脆弱点。
- 研究结果为该方法可行性的概念验证,包括其局限性。
- 作者认为该策略可适用于其他癌症实体及其他分子数据类型,其在模型系统和观察数据层面的放大潜力值得进一步研究。
研究设计与样本
- 对一组人胶质母细胞瘤细胞系进行整合分析。
- 用qRT-PCR分析38个DNA损伤应答调节因子的mRNA表达水平。
- 用克隆形成存活实验评估对放疗(单次和分次模式)和/或替莫唑胺的固有抵抗。
- 通过降维提取抵抗评分并与mRNA表达数据进行相关分析。
- 对正相关系数的顶级候选者通过克隆形成存活实验中的药理学抑制和残余γH2AX/53BP1 foci染色DNA修复分析进行验证。
主要发现
- 对单次放疗的固有抵抗与PARP1、NBN、BLM、ATR和LIG4的mRNA表达水平呈强正相关。
- 对分次放疗的固有抵抗同样与PARP1、NBN、BLM、ATR和LIG4的mRNA表达水平呈强正相关。
- AZD-6738抑制ATR导致胶质母细胞瘤细胞稳健且剂量依赖的放射增敏,而L189抑制LIG4无明显影响。
- 对替莫唑胺的抵抗与MGMT的mRNA表达水平呈强正相关,也与ATM的mRNA表达水平相关。
- ATM抑制在MGMT低表达胶质母细胞瘤细胞中对替莫唑胺治疗显示轻微增敏效应。
局限性
- 作者在结论中写明该研究结果为其方法可行性的概念验证,并包括其局限性,但原文摘要未逐条列出具体局限性内容。
- 作者在结论中写明该策略在模型系统和观察数据层面的放大潜力值得进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Inherent resistance to radio/chemotherapy is one of the major reasons for early recurrence, treatment failure, and dismal prognosis of glioblastoma. Thus, the identification of resistance driving regulators as prognostic and/or predictive markers as well as potential vulnerabilities for combined modality treatment approaches is of pivotal importance. METHODS: We performed an integrative analysis of treatment resistance and DNA damage response regulator expression in a panel of human glioblastoma cell lines. mRNA expression levels of 38 DNA damage response regulators were analyzed by qRT-PCR. Inherent resistance to radiotherapy (single-shot and fractionated mode) and/or temozolomide treatment was assessed by clonogenic survival assays. Resistance scores were extracted by dimensionality reduction and subjected to correlation analyses with the mRNA expression data. Top-hit candidates with positive correlation coefficients were validated by pharmacological inhibition in clonogenic survival assays and DNA repair analyses via residual γH2AX/53BP1-foci staining. RESULTS: Inherent resistance to single-shot and similarly also to fractionated radiotherapy showed strong positive correlations with mRNA expression levels of known vulnerabilities of GBM, including PARP1, NBN, and BLM, as well as ATR and LIG4-two so far underestimated targets. Inhibition of ATR by AZD-6738 resulted in robust and dose-dependent radiosensitization of glioblastoma cells, whereas LIG4 inhibition by L189 had no noticeable impact. Resistance against temozolomide showed strong positive correlation with mRNA expression levels of MGMT as to be expected. Interestingly, it also correlated with mRNA expression levels of ATM, suggesting a potential role of ATM in the context of temozolomide resistance in glioblastoma cells. ATM inhibition exhibited slight sensitization effects towards temozolomide treatment in MGMT low expressing glioblastoma cells, thus encouraging further characterization. CONCLUSIONS: Here, we describe a systematic approach integrating clonogenic survival data with mRNA expression data of DNA damage response regulators in human glioblastoma cell lines to identify markers of inherent therapy resistance and potential vulnerabilities for targeted sensitization. Our results provide proof-of-concept for the feasibility of this approach, including its limitations. We consider this strategy to be adaptable to other cancer entities as well as other molecular data qualities, and its upscaling potential in terms of model systems and observational data levels deserves further investigation.
引用
- Schnöller LE, Albrecht V, Brix N, et al. Integrative analysis of therapy resistance and transcriptomic profiling data in glioblastoma cells identifies sensitization vulnerabilities for combined modality radiochemotherapy. Radiat Oncol. 2022. PMID: 35440003. doi:10.1186/s13014-022-02052-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。